GlassScriptPhysician profile
Kristin E Owens
NPI 1487074969
$2,057.03
in general payments reported to CMS, 2019-2025
28 companies · $571 in 2025
The $571 reported for 2025 was more than what 83% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $130 · 2020: $35.15 · 2021: $204 · 2022: $352 · 2023: $429 · 2024: $336 · 2025: $571.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,336.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,336.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $522.57 | 2019-2025 | |
| Shield Therapeutics INC | $222.37 | 2023-2025 | Accrufer |
| Exeltis, USA INC. | $157.89 | 2019-2025 | Slynd |
| Daiichi Sankyo INC. | $133.73 | 2023-2025 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $129.16 | 2019-2025 | |
| Millicent US INC | $83.94 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Hologic Sales and Service, LLC | $80.53 | 2024-2025 | Acessa Provu System, Novasure, Myosure Tissue Removal Device |
| Biogen, INC. | $79.93 | 2025 | Zurzuvae |
| Mayne Pharma Commercial LLC | $75.94 | 2022-2025 | |
| Organon LLC | $58.97 | 2022-2024 | |
| Novo Nordisk INC | $55.17 | 2023-2025 | Wegovy, Saxenda |
| Sumitomo Pharma America, INC. | $49.19 | 2023-2025 | Myfembree |
| Pfizer INC. | $43.32 | 2023-2025 | |
| Astellas Pharma US INC | $41.82 | 2023 | Veozah, Myrbetriq |
| Pacira Pharmaceuticals Incorporated | $40.46 | 2024 | Exparel |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $37.50 | 2023-2025 | Gardasil 9 |
| Amgen INC. | $31.61 | 2024-2025 | Evenity, Prolia |
| Seqirus USA INC | $29.92 | 2025 | Flucelvax |
| Myovant Sciences INC. | $29.08 | 2022 | |
| Mylan Pharmaceuticals INC. | $27.57 | 2022 | |
| Becton, Dickinson and Company | $20.52 | 2025 | Hemosphere |
| Coopersurgical, INC. | $20.17 | 2024 | Paragard T 380a |
| Pharmacosmos Therapeutics INC. | $19.65 | 2023 | Monoferric |
| Janssen Biotech, INC. | $16.96 | 2020 | |
| Scynexis, INC. | $16.50 | 2022 | |
| Medtronic, INC. | $14.04 | 2023 | Truclear |
| Avion Pharmaceuticals | $13.42 | 2022 | |
| Channel Medsystems, INC. | $5.10 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristin Owens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.